Spots Global Cancer Trial Database for gvhd prophylaxis
Every month we try and update this database with for gvhd prophylaxis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole | NCT03434704 | Transplant-Rela... Leukemia, Acute Myelodysplastic... Graft Vs Host D... Fungal Infectio... | Conditioning tr... PBSC graft GvHD prophylaxi... Primary antifun... | 18 Years - | IRCCS San Raffaele | |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | NCT00923845 | Renal Cell Carc... Graft-Versus-Ho... Engraftment Syn... | Pentostatin Sirolimus Cyclophosphamid... Allogeneic Hema... Th2 rapa cells Donor Lymphocyt... Induction Thera... GVHD prophylaxi... Donor Hematopoi... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego | |
| Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma | NCT03700450 | Multiple Myelom... | Cyclophosphamid... | 18 Years - 65 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Comparing Post-Transplant Cyclophosphamide as GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients | NCT04314219 | Acute Lymphobla... Acute Myeloid L... | Cyclophosphamid... Methotrexate | 14 Years - 65 Years | King Faisal Specialist Hospital & Research Center | |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV | NCT05470491 | HIV Hematologic Mal... | RIC GVHD prophylaxi... allo HCT Plerixafor Maraviroc | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole | NCT03434704 | Transplant-Rela... Leukemia, Acute Myelodysplastic... Graft Vs Host D... Fungal Infectio... | Conditioning tr... PBSC graft GvHD prophylaxi... Primary antifun... | 18 Years - | IRCCS San Raffaele | |
| Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma | NCT03700450 | Multiple Myelom... | Cyclophosphamid... | 18 Years - 65 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) | NCT00096460 | Recurrent Grade... Recurrent Grade... Recurrent Grade... Follicular Lymp... | Cyclophosphamid... Filgrastim Chemotherapy or... Non-myeloablati... Allogeneic tran... Autologous tran... Rituximab maint... GVHD Prophylaxi... | - 75 Years | Medical College of Wisconsin | |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
